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Summary.-Adenosine deaminase (EC 3.5.4.4., ADA) has been measured in the blast
cells of 36 patients with acute lymphoblastic, acute myeloid, chronic myeloid and
chronic myeloid blast crisis leukaemia. Particularly high levels were found in
acute lymphoblastic and chronic myeloid blast crisis patients. The measurement
of ADA may be useful diagnostically in the undifferentiated acute leukaemias and in
detecting the early onset of blast crisis in chronic myeloid leukaemia. Possible
reasons for the elevation of ADA in malignant cells are discussed.
ADENOSINE deaminase (EC 3.5.4.4.,
ADA) activity has been demonstrated in a
variety of mammalian tissues (Conway
and Cooke, 1939; Brady, 1942; Brady
and O'Donovan, 1965; Hall, 1963) and
especially in tissues with a high content
of lymphoid cells, such as lymph nodes,
spleen, appendix and Peyer's patches.
Several studies of serum ADA activity in
disease states have been made, including
malignant and non-malignant conditions
(Koehler and Benz, 1962; Goldberg,
Fletcher and Watts, 1966; Goldberg,
1965) and elevations have been detected
in cancer patients, especially those with
bronchial carcinoma (Nishihara etal., 1970)
and hepatic neoplasms (Raczynska, Jonas
and Krawczynski, 1966; Goldberg et al.,
1966). Particularly high serum levels have
been reported in infectious mononucleosis
(Koehler and Benz, 1962). In addition to
raised levels of the enzyme, isozyme
studies have revealed at least 3 and
possibly 5 different molecular species of
ADA in normal tissues (Cory, Weinbaum
and Suhadolnik, 1967; Nishihara et al.,
1973; Hirschhorn et al., 1973), in bronchial
carcinoma (Nishihara et al., 1973), and
acute leukaemia (Bloom, 1972). Speci-
fically in acute myelomonocytic leukaemic
cells, Bloom has demonstrated the pres-
ence of an ADA species which is absent
from normal lymphocytes, granulocytes,
spleen and lymph nodes. In comparing
purine metabolizing enzymes in leucocytes
from normal subjects and patients with
lymphoblastic leukaemia, Scholar and
Calabresi (1973) reported normal or low
levels in chronic lymphatic leukaemia
(CLL), but raised levels (greater than
700%o) in a 6-year-old boy with acute
lymphoblastic leukaemia.
These findings prompted us to measure
the ADA activity in malignant cells from
patients with all forms ofleukaemia in the
hope that levels of this enzyme might
show distinction between acute and chron-
ic lymphocytic and granulocytic (myelo-
blastic) leukaemia. We report here the
results of studies on 36 patients whose
diagnoses include acute myeloid leu-
kaemia (AML), acute myelomonocytic
leukaemia (AMML), acute lymphoblastic
leukaemia (ALL), chronic myeloid leu-
kaemia (CML), chronic myeloid leukaemia
in its blastic phase (CMBLC), chronic
lymphatic leukaemia (CLL) and acute
promyelocytic leukaemia (PML).
PATIENTS AND METHODS
The patients used in this study were under
the care of the physicians at the Royal
Marsden Hospital, Sutton or St Bartholo-
mew's Hospital, London. All the cases ofADENOSINE DEAMINASE ACTIVITY IN LEUKAEMIA
acute leukaemia were studied at the time of
diagnosis, before any chemotherapy, and all
assays were performned on the day of vene-
puncture.
Adenosine and inosine were obtained from
Sigina Chemical Co., St Louis, Missouri,
U.S.A., purified adenosine deaminase from
calf intestine from the Boehringer Corpora-
tion (London) Ltd, Ficoll from Pharmacia
Fine Chemicals, Uppsala, Swteden and Triosil
from Nyegaard and Co., Oslo, Norway.
Separation of blast cells. The blast cells
were separated from freshly obtained hepari-
nised blood by the technique of Boyum
(1966-68): 10 ml of blood wrere diluted with
3 parts of0-9%o NaCl and 8 ml aliquots of the
blood-NaCl mixture wN-ere carefully layered
over 3 ml of Ficoll-Triosil solution (24 parts
Ficoll to 10 parts Triosil) in centrifuge tubes
and spun at 400 g for 40 min at 20°C. The
blast cells (and lymphocytes) separated at
the plasma-Ficoll interface and were re-
moved with a pipette, yielding a preparation
containing not less th-an 9500 mononuclear
cells. Granulocytes sedimented wNith ery-
throcytes at the bottom of the tube. Cell
populations were checked bv preparing
Giemsa films of the pipetted cells and it wAas
confirmed that in addition to lymphocytes
and lymphoblasts, the blast cells in acute
myeloid leukaemia and the blastic phase of
chronic myeloid leukaemia also separated at
the plasma-Ficoll interface.
Preparation of cell extracts. All pro-
cedures were carried out in duplicate at 4°C.
The cells w;ere washed tw%ice by resuspending
in 0-9%o saline and recentrifuging, and the
pellet finally taken up in 3 ml of 0415 mol/l
phosphate buffer pH 71 after counting in a
Neubauer haemacytometer (Gallenkamp) the
cell concentration was adjusted to between
0-3-1-0 x 107/ml before disrupting a 3 ml
volume of cells by sonication (45 s at 20
kHz, MSE Ultrasonicator). The suspension
was then centrifuged at 800 q for 5 min and
the supernatant used for the enzyme assay.
Adenosine dearn?inase assay. The extracts
were assayed for adenosine deaminase activity
by a modification of Kalekar's technique
(Kalckar, 1947), using a double beam Cary
16 spectrophotometer. The sample cuvette
(1 cm path length) contained I 0 ml adenosine
(0-2 mnmol aqueous), (2-x) ml 0(15 mol/l
phosphate buffer pH 7-1 equilibrated at 30°C,
and the reaction started by the addition of
x ml (in the range 0-01 to 0 2 ml) extract,
39
iiaking a total volume of 3-0 ml. The ref-
erence cuvette (1 cm) contained 1-0 ml of
0-1 mmol adenosine and 2-0 ml 0-15 mol/l
phosphate buffer pH 7-1. The reaction was
folloNwed at 265 nm and was linear for at least
5 min. One unit of adenosine deaminase
activity is defined as the amount of enzyme
in 107 cells which produces a decrease in
optical density of 0-010 per min under the
con(litions described (Hall, 1963).
RESULTS
Of the 41 subjects studied 26 (63%)
were male and 15 (37o%) female with a
mean age of 38, ranging from 11 to 77
years. The lymphocytes from 5 healthy
volunteers were used for controls and the
other groups consistcd of 14 cases of
AMIL, 7 cases of ALL, 7 cases of CML, 6
cases of CMLBC aind one each of CLL and
PAIL. Table I shows the total and differ-
ential white cell count of the peripheral
blood samples taken and the individual
levels of ADA in the blast cells of the
patients investigated in this study. There
was no difference in the differential pro-
portion of blast cells and lymphocytes in
the two major groups ALL and AML,
where the mean blast count for ALL was
76% with 11% lymphocytes, and for
AMIL 75%o with 10% lymphocytes. Table
II shows the meain, standard deviation
and range of ADA in the cells measured,
while the individual variation within
diagnostic groups is illustrated in the
scattergram (Fig. 1). ADA is a cyto-
plasmic enzyme (Dixon and Webb, 1964).
The mean cell size varies considerably
between one case of acute leukaemia and
another, both within and between diag-
nostic groups, and no correction for differ-
ences in cell size has been made in this
study. Nevertheless, it should be noted
that there is a larger cytoplasmic/nuclear
ratio in myeloblasts than lymphoblasts,
but the ADA levels in the latter are con-
siderably greater than in the former.
The level of ADA in the lymphocytes
from normal subjects ranged from 1P2 to
4.3 with a mean of 2 8 u, and the mean
level for each leukaemic group was sig-
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TABLE II. Adenosine Dearninase
Activity in Leukaemic Patients
Diagniosis
Normal
ALL
AML
CML
CMLBC
CLL
PML
Adenosine dleaminase
u/107 cells
No. of ,
patients Mean S.D.* Range
5 2 8 ± 12 1 2-4 3
7 100 --106 11 3-297
14 14 4 ± 11 6 0-41 5
7 5-2 -1- 1 9 25 5-80
6 45 5 ± 35 2 10o0-112
1 - 23
1 0.0
Adenosine deaminase measured in the blast cells of
36 patients and the lymphocytes of 5 healthy
volunteers. One unit of adenosine deaminase is
defined as the amount of enzyme in 107 cells which
produced a decrease in optical density of 0 010 per
min undei the described conditions. *SD=
standard deviation of the mean.
ADA Units
_2^
0
.
0
0
0
_
0 _aw 0 *
Cont ALL AML CML CLL PML CMLBC
FIG. 1. Scattergram ofindividual ADA levels
in the blast cells ofpatients with acute lym-
phoblastic leukaemia (ALL), acute myeloicl
leukaemia (AML), chronic myeloid leuik-
aemia (CML), chronic myeloid leukaemia
blast crisis (CMLBC), chronic lymphocytic
leukaemia (CLL) and acute promyelocytic
leukaemia (PML). The lymphocytes from
healthy volunteers were used for controls.
Units ofADA see textand legend toTable II.
nificantly elevated compared with this
[Student's t or Cochran's t test (Cochran,
1967)]. The group mean for ALL was
100 u with a wide range from 113 to the
highest recorded ADA level of any of the
patients studied at 297 u: the lowest value
ofany patient with ALL was 250%greater
than the highest value for any of the
healthy subjects. In the AML group the
levels were much lower than in ALL, with
a mean of 14-4 u ranging from 0 to 41-5.
Three of the 14 AML patients had ADA
levels within or below the normal range,
but the group mean was significantly
different from normal (P < 0.05). The
one case of promyelocytic leukaemia had
no detectable ADA in his promyelocytes.
In chronic myeloid leukaemia it was found
that there was a marked difference in
ADA level between the quiescent phase of
the disease (CML) and the accelerated
blast crisis phase (CMLBC). In the
former the ADA levels ranged from 2-5 to
8 0 u (mean 5.2), whereas in the blast
crisis patients the mean level was higher
(45.5), though there was a wider scatter,
ranging from 10-0 to 112-5 u. There is a
significant difference between the ADA
levels in this last group and the normals;
in the CML group, although there is an
overlap with the normal range, the
difference between the group means (nor-
mal vs CML) is significant (P < 0.05).
Chronic lymphatic leukaemia was not
investigated to the same extent as chronic
myeloid leukaemia, in view of the series
of Scholar and Calabresi (1973).
The individual variation between
groups can be appreciated from the
scattergram, which shows that the highest
individual levels were found in ALL and
CMLBC, with much lower levels in AML
and especially CML. Comparing the ALL
with AML patients, the marked variation
in the lymphoblastic group meant that
the Student's t test was not applicable;
Cochran's t test was therefore applied and
showed that the group means were not
significantly different (P > 0.05). There
was, however, a statistically significant
difference between the group means of the
CML patients and those in CMLBC.
DISCUSSION
An accurate diagnosis to distinguish
ALL from AML is essential if the optimal
',UU
250
200-
150-
100-
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treatment is to be initiated with minimal
delay, since there is a marked difference in
response to cytotoxic drugs in these two
diseases. Remission induction in AML
employs combinations of cytosine arabino-
side with daunorubicin or adriamycin,
whereas vincristine and prednisolone are
used in ALL. At present the classifica-
tion of acute leukaemias into these two
major subtypes, ALL and AML, is pre-
dominantly made by techniques such as
Romanowsky staining of blood and mar-
Irow films, supplemented by periodic acid
Schiff(PAS) andSudanblackpreparations.
Nevertheless, in approximately 10%0 of
cases of acute leukaemia the cell strain
is undifferentiated by thesQ techniques
(Beard and Hamilton Fairley, 1974).
Furthermore, PAS positivity was seen in
only 50%0 of the series of ALL patients
recently reported by Atkinson et al. (1974).
The overlap between ALL and AML cells
with respect to their ADA levels means
that this enzymatic assay cannot be used
diagnostically in isolation but, used in
conjunction with the above techniques,
the presence of a very high ADA or of an
ADA level within the normal range may
be of use diagnostically when evaluating
undifferentiated acute leukaemias. We
have already found this to be the case.
Three patients with negative staining to
both PAS and Sudan black had ADA
levels of 128 u, 78 u and 0 u; a dramatic
response to vincristine and prednisolone,
typical of ALL, was seen in the first two
patients with very high ADA levels,
whereas the patient with no detectable
ADA was treated as an AML and
responded to cytosine arabinoside and
adriamycin.
There are two interesting features of
the ADA levels measured in chronic
myeloid leukaemia. The first is the closer
similarity between CMLBC and ALL cells
than CMLBC and AML cells; there is
controversy as to the nature ofthe cell line
in CMLBC but therapeutically it has been
found that the greatest response in blast
crisis has been achieved with regimens
similar to those used for acute lympho-
blastic leukaemia (Canellos et al., 1971;
Marmont and Damasio, 1973). Here we
have shown a metabolic similarity be-
tween the CML blast cell and the lympho-
blast that is much less evident in the
myeloblast.
The second feature is the distinction
between ADA levels in CML in its quies-
cent and blastic phases; recognition of
fulminant CMLBC is not difficult clinically
but the onset is frequently insidious and
an enzymatic marker of early metamor-
phosis provides the opportunity to initiate
a change in therapy at an earlier stage than
is at present possible. We are now mak-
ing a sequential study of the ADA levels
of CML patients with the aim of detecting
the onset of blast crisis at its earliest
transformation.
The reason for the high levels in some
circulating leukaemia cells might be found
in a consideration of the role of this
enzyme in normal cells. Barnes (1940)
was the first to show that circulating
lymphocytes contained appreciable ADA
activity and later Hall (1963) showed that
even higher levels were present, together
with antibody, in the plasma blasts which
are discharged into the circulation during
the immune response. More recently, a
number of cases of severe congenital com-
bined immunodeficiency have been des-
cribed in association with profound lym-
phopenia and absence of ADA (as meas-
ured in erythrocytes) (Giblett et al., 1972;
Dissing and Knudsen, 1972; Yount et al.,
1974). These findings suggest that ADA
is associated normally with lymphocytes
and lymphocyte proliferation, and that its
absence may be associated with impaired
lymphocyte proliferation and immune
responsiveness. These observations are
consistent with the high levels ofADA that
we have demonstrated in the cells of
lymphoblastic leukaemia. Furthermore,
it has been shown that adenosine, the
substrate for ADA, is toxic at low con-
centration to certain mammalian cells, in
particular to cells of the lymphoid system
by virtue of interfering with the endo-
genous synthesis of pyrimidines in a late
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stage of the biosynthetic pathway, which
may account for the lymphopenia seen in
patients with congenital absence of ADA
(Ishii and Green, 1973).
The increased levels of ADA measured
in human leukaemic cells may represent
a detoxication mechanism, preventing the
accumulation of potentially toxic levels of
adenosine and adenosine nucleotides aris-
ing from the increased metabolic activity
in the malignant cell. Alternatively, the
increased ADA activity may represent an
increased demand for purines via the
salvage pathways, although the signifi-
cance of purine salvage, as opposed to de
novo synthesis in the human leucocyte is
controversial (Cline, 1965; Murray, 1971).
Experiments are being performed to test
these hypotheses.
One of us, J.F.S., is supported by a
Cancer Research Campaign Fellowship.
We wish to thank Dr J. G. Hall for draw-
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